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Abstract
Background: Musculoskeletal impairment (MSI) is an important cause of morbidity and mortality worldwide,
especially in developing countries. Prevalence studies for MSI in the developing world have used varying
methodologies and are seldom directly comparable. This study aimed to develop a new tool to screen for and
diagnose MSI and to pilot test the methodology for a national survey in Rwanda.
Methods: A 7 question screening tool to identify cases of MSI was developed through literature review and
discussions with healthcare professionals. To validate the tool, trained rehabilitation technicians screened 93
previously identified gold standard 'cases' and 86 'non cases'. Sensitivity, specificity and positive predictive value
were calculated. A standardised examination protocol was developed to determine the aetiology and diagnosis of
MSI for those who fail the screening test. For the national survey in Rwanda, multistage cluster random sampling,
with probability proportional to size procedures will be used for selection of a cross-sectional, nationally
representative sample of the population. Households to be surveyed will be chosen through compact segment
sampling and all individuals within chosen households will be screened. A pilot survey of 680 individuals was
conducted using the protocol.
Results: The screening tool demonstrated 99% sensitivity and 97% specificity for MSI, and a positive predictive
value of 98%. During the pilot study 468 out of 680 eligible subjects (69%) were screened. 45 diagnoses were
identified in 38 persons who were cases of MSI. The subjects were grouped into categories based on diagnostic
subgroups of congenital (1), traumatic (17), infective (2) neurological (6) and other acquired(19). They were also
separated into mild (42.1%), moderate (42.1%) and severe (15.8%) cases, using an operational definition derived
from the World Health Organisation's International Classification of Functioning, Disability and Health.
Conclusion: The screening tool had good sensitivity and specificity and was appropriate for use in a national
survey. The pilot study showed that the survey protocol was appropriate for measuring the prevalence of MSI in
Rwanda. This survey is an important step to building a sound epidemiological understanding of MSI, to enable
appropriate health service planning.
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Background
Musculoskeletal impairment (MSI) is an important cause
of morbidity and mortality worldwide, [1] however the
exact magnitude of the global burden of disease due to
MSI is unknown. The World Health Organisation (WHO)
estimated that 10% of any population has a disability, of
which 1.5% requires rehabilitation[2]. WHO also esti-
mated that there is a disproportionate burden of MSI
borne by the developing world[3,4] as 80% of people liv-
ing with disabilities live in developing countries and
many do not have access to rehabilitation services.
There have been few surveys conducted to assess the mag-
nitude and causes of MSI in developing countries and
these have used a variety of different methodologies [5-
12] so the results from the surveys are not easily compara-
ble. The majority of studies look at disability as a whole,
rather than physical disability or MSI. Some of these sur-
veys have focused on the total population, while others
have focussed on children or other age groups. Most sur-
veys have been undertaken in districts or communities
rather than on a national level.
Rwanda is a poor country in central Africa, with a popula-
tion of around 8.2 million people in 2002 [13]. Rwanda
suffered a major internal war in 1994 during which up to
one million people were killed. In 1995, Handicap Inter-
national carried out an all-age nationwide survey in
Rwanda and estimated that the prevalence of disability
was 0.58%, of which physical deformities were the main
cause [Enquête Nationale sur l'Ampleur du Handicap au
Rwanda : Résultats et recommandations pour l'élabora-
tion d'un plan. In. Kigali: Handicap International, Min-
istère de la Réhabilitation et l'Intégration Sociale,
Ministère du Travail et des Affaires Sociales 1995]. This
low prevalence was thought to be the result of selection
bias due to the inaccessibility of the population so soon
after the war. A community based rehabilitation survey in
Kigali estimated a prevalence of disability of 1.8% in 1997
[Jackson H.E. Prevalence of Disability Study, Christian
Blind Mission, 2002]. There were concerns that this was
an underestimate because political sensitivity may have
caused people to withhold information about disabled
members of their family. In contrast, the national census
in 2002 estimated the prevalence of all disabilities at
4.8%[13]. It is because of this disparity in data that the
Ministry of Health of Rwanda requested that a national
survey be conducted to estimate the burden of MSI, to
enable planning of future surgical and rehabilitation serv-
ices.
The aim of this study was to develop a new tool to screen
for and diagnose MSI and to develop and to pilot test the
methodology for a national survey of MSI in Rwanda. The
objectives of the national survey of MSI were:
1. To estimate the prevalence of MSI in Rwanda
2. To identify the causes of MSI in Rwanda
3. To estimate the coverage of MSI services in Rwanda
4. To assess the barriers to uptake of MSI services
5. To evaluate quality of life among people with MSI
Methods
Definition of musculoskeletal impairment
A definition of MSI was developed by taking as a starting
point the standard ICF definition of impairment as "a loss
or abnormality in body structure or physiological func-
tion". We made this specific to the musculoskeletal sys-
tem, and we specifically included chronic pain, and added
a minimum time duration of one month to exclude minor
injuries and self limiting conditions. We also reviewed
published literature and had consensus discussions with
healthcare professionals managing MSI, including physi-
otherapists, rehabilitation technicians and doctors. The
definition was then checked to make sure it covered all
commonly diagnosed cases of MSI that were referred to
existing services and were likely to be seen in the survey.
The definition of MSI that we used was:
"a lack of normal structure or function, or an increase in pain
or discomfort in the integument, muscles, bone or joints of the
body of an individual, that has lasted at least one month and
which limits function of the musculoskeletal system."
Developing the survey tools
The survey tool used comprised two parts. Firstly a screen-
ing tool which was applied to everyone in the survey to
identify suspect cases of MSI. Those who failed the screen-
ing tool (i.e. answered 'yes' to any of the first six questions
in the screening tool, and had a condition that had lasted
for at least one month or was permanent) were suspect
cases of MSI and underwent the second part of the survey
tool, a standardised examination protocol to confirm case
status.
Development of the screening tool
To develop a screening tool for MSI we conducted a liter-
ature search to identify similar tools. Zaman's 'ten ques-
tion questionnaire (TQQ)[14] was chosen as a starting
point. The TQQ is a tool to screen for all types of disability
that has been used in a number of studies [6,10]. We
removed the questions that did not deal with physical
impairment (e.g. 'Does your child appear to have diffi-
culty in hearing?' and 'Compared with other children does
the child have difficulty seeing, either in the daytime or at
night?'). We directed the questions to the first person so
that they could be used for an adult, and separated ques-BMC Musculoskeletal Disorders 2007, 8:30 http://www.biomedcentral.com/1471-2474/8/30
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tions that asked for many concepts at once. Thus ques-
tions that asked about arms and legs together were
separated into two questions. The screening tool was
tested against the diagnoses to see if it could accurately
identify them. Discussions were held with physiothera-
pists, paediatricians, orthopaedic surgeons, rehabilitation
assistants and patients in focus groups in Malawi where
the concepts of the tool were discussed and altered accord-
ing to make the questions easy to understand. We then
had a screening tool of 7 questions which asked partici-
pants about difficulties using the various parts of their
musculoskeletal system difficulties with walking, whether
they used a mobility aid, whether they felt they had any
physical deformity, and the duration of their impairment
(Table 1). Preparatory work was undertaken in Malawi as
one of the authors (CL) was based there, and the pathol-
ogy encountered was assumed to be similar to Rwanda.
It will be noted that question 6 in the screening tool asks
about seizures and convulsions. From a purely scientific
point of view these are not physical impairments and
could have been excluded, but they were included in the
protocol because in Rwanda patients with seizures often
presented at physical disability facilities, and also because
seizures are associated with other physical impairments
such as burns and cerebral palsy. In future uses of this sur-
vey this component could easily be left out.
Tool validation was carried out in Malawi. Four rehabili-
tation technicians were trained to use the tool. 179 partic-
ipants were screened, of whom 93 were identified by a
gold standard as cases of MSI, and 86 were non-cases. The
gold standard of who was or was not a case was deter-
mined by the assessment of an independent orthopaedic
surgeon and physiotherapist, who were familiar with the
definition of MSI. The rehabilitation technicians trained
in the use of the screening questions and physical obser-
vations then independently applied the tool to all the
cases and non cases. Intra-observer correlation, sensitivity,
specificity and positive predictive value (PPV) were calcu-
lated.
Development of the standardised examination protocol
Individuals who failed the screening test (i.e. suspected
cases of MSI) were further examined using the standard-
ised examination protocol. It includes a structured physi-
cal examination testing key components of the
musculoskeletal system, examining function (e.g. walk-
ing), as well as examining the affected part of the body to
determine the nature of the impairment. It also includes a
structured interview to gain a more detailed history of the
musculoskeletal impairment. This section was developed
to confirm and diagnose the MSI and was developed
through consensus with health care professionals. It com-
prises 7 sections including:
a. Examination: The physiotherapists examined the case to
help with determining the diagnoses and severity of the
MSI. They carried out a structured examination where they
asked the individual to carry out tasks which included
walking and picking up small items with their thumb and
index finger. They also examined the affected area. They
were trained to examine musculoskeletal components of
the affected region they were examining e.g. the range of
motion of a joint, or the length of a limb.
b. Diagnosis: The standardised examination protocol
includes an algorithmic classification system for diagnosis
which allowed the non-medical health care professionals
to identify potential diagnoses of the MSI without access
to further investigation modalities. The algorithm led the
physiotherapist to question what was the aetiological
cause of the impairment and then within each large aetio-
logical category, there were options of diagnosis which
they further determined by examination and questioning
of the case. The five main subgroups of diagnoses were
defined as congenital, traumatic, infective, neurological
and other acquired.(see Table 2) Up to two diagnoses
were permissible per identified case of MSI. The diagnos-
tic list was drawn up after consultation with in country
health care professionals dealing with MSI over several
years. The diagnoses can if wished be mapped onto ICD10
(International Classification of Diseases) codes, but this
has not been done in Table 2 for simplicity, since each
diagnoses includes a variety of different ICD10 codes.
c. Area affected and nature of problem: In the standardised
examination protocol an examiner would also record
information on the area of the body affected and the
nature of the problem. The nature of the problem could
include total absence, additional part, and deviating posi-
tion (as outlined in ICF).
d. Aetiology: Where this was known it was recorded on the
standardised examination protocol. It was determined by
questioning that case about when the impairment devel-
oped and how it came about. Additional questions were
posed to gain more information. For example if an infec-
tive cause was suspected the case would be questioned
about systemic symptoms, or discharge from the area
affected. The physiotherapists were trained as to what
questions to ask for each aetiology available which
included road traffic accidents, war, infection and famil-
ial.
e. Severity: Severity was determined using the parameters
for the percentage of function outlined in the WHO refer-
ence book International Classification of Functioning
(ICF)[15]. A loss of function of 5–24% was mild, 25–49%
was moderate and 50–90% was severe.BMC Musculoskeletal Disorders 2007, 8:30 http://www.biomedcentral.com/1471-2474/8/30
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f. Quality of life : The EQ-5D is a public domain quality of
life questionnaire from the Euro-Qol group, which has
been validated in a number of countries and cultural set-
tings[16]. It allows the participant to indicate their health
state by indicating the most applicable statement in five
parameters, including mobility. The EQ-5D also includes
a visual analogue scale (VAS) which is a self-scoring meas-
ure of current health status from 0 (worst imaginable
health state) to 100 (best imaginable health state).
g. Treatment: The standardised examination protocol
recorded treatment that had already been given and
allowed the interviewer to assess treatment needed.
Guidelines were given to the physiotherapist during train-
ing as to likely treatment modalities to consider for differ-
ent diagnoses. So for example for talipes equinovarus it
was suggested that up to age 1 physiotherapy and
splinting alone could be considered, but above this age
surgery would become more of a consideration depend-
ing on the function of the case.
h. Barriers to treatment: The standardised examination pro-
tocol recorded the patients own understanding of reasons
why they may not have had treatment. These included
services not being available, or the patient being unable to
afford available services.
Translation
The tool was translated and back translated from English
into Kinyarwandan by two medical translators, independ-
ently of each other.
Pilot study
The national survey of MSI was planned as an all age pop-
ulation based survey covering the whole of Rwanda, using
the screening tool and standardised examination protocol
to screen for and diagnose MSI.
Following training, a pilot survey of 680 individuals of all
ages in nine clusters was carried out, prior to the national
survey.
Sampling strategy
Six rural and three urban clusters were selected using a
stratified probability-proportionate-to-size sampling
strategy in two of the twelve provinces of Rwanda. A
multistage stratified cluster random sampling with proba-
bility proportional to size procedure was chosen as the
strategy for selection of a cross sectional, representative
sample of the population of all ages. The primary sam-
pling units (clusters) were the enumeration areas deline-
ated in the national 2002 census. A list of enumeration
areas was obtained from the government. Nine clusters
were selected by probability proportional to size.
In each cluster a modified compact segment sampling
method was used to identify the 80 people to be screened
and examined. Maps were obtained for each of the
selected clusters. The maps provided delineated "nyum-
bakumi" which were groups of ten households in the enu-
meration areas. (in Kinyarwandan 'nyumba' = house, and
'kumi' = ten) prior to the arrival of the screening team,
trained personnel would visit the cluster and meet with
the local administrative heads to determine changes to the
local population and get information about the number
of people in each of the nyumbakumi. Once they had
updated the maps then the enumeration area was divided
into segments of 80 people and one of the segments was
chosen at random as the one to be sampled (e.g. if the
population size of the enumeration area was 400 people
then it would be divided into five segments). The segment
would be informed of the need to be present on the day
of examination. Eligible subjects were defined as residents
of the household, that is, an individual who normally
sleeps and eats their meals in that household for at least 6
months per year.
Survey data collection procedures (see Fig 1)
Screening and examination of individuals was undertaken
in the household using the screening tool and standard-
ised examination protocol described above. Each team
consisted of one physiotherapist, one nurse and one
driver. The team physiotherapist visited and screened
Table 1: Screening questionnaire
Screen for musculoskeletal impairment Yes No
1. Is any part of your body missing or misshapen? ❍❍
2. Do you have any difficulty using your arms? ❍❍
3. Do you have any difficulty using your legs? ❍❍
4. Do you have any difficulty using any other part of your body? ❍❍
5. Do you need a mobility aid or prosthesis? ❍❍
6. Do you have convulsions, involuntary movement, rigidity or loss of consciousness? ❍❍
If any of the answers are "yes"
7. Has it lasted more than one month or is it permanent? ❍❍BMC Musculoskeletal Disorders 2007, 8:30 http://www.biomedcentral.com/1471-2474/8/30
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every member of every household in a segment. Consent
was taken, first from the head of the household and then
from the individual, after explanation of the examination
procedures. The screening test was applied for people aged
5 yrs and above, and for children less than 5 years the
questions were answered by proxy by the child's main
carer. those who failed the screening test (i.e. suspect
cases) underwent the standardised examination protocol,
along with a random 10% of people who passed the
screening test (i.e. suspect non-cases). The supervisors
checked items of all completed forms in the field. Non-
responders were revisited throughout the day, but those
who were finally unavailable were recorded as 'believed to
have MSI' (with or without treatment) or 'believed not to
have MSI', after consultation with family and community
leaders.
Data entry
Data was double entered by data clerks onto a pre-pre-
pared database in Epi-Data with consistency checks and
comparative validation of double entered data. Analysis
was performed in Stata 9.0.
Table 2: diagnostic criteria for the survey
Diagnosis Definition
A Congenital deformity
A1 Polydactyly More than five digits on one or both hands (can also be on the feet)
A2 Syndactyly Digits joined together by skin or soft tissue (can also be on the feet)
A3 Other upper limb deformity Any congenital abnormality of upper limb or foot not already described
A4 Club foot Eqinus and varus deformity of foot which is not passively correctable
A5 Other lower limb deformity Any congenital abnormality of lower limb or foot not already described
A6 Spine deformity Any congenital deformity of spine
A7 Cleft lip/palate Unilateral or bilateral defect in continuity of upper lip, with or without associated defect in palate
A8 Multiple abnormalities Congenital abnormalities in more than one site, not including polydactyly
A9 Other – specify Other congenital abnormality not described above
BT r a u m a
B1 Fracture non/malunion Un-united fracture more than six months since injury or fracture healed with deformity e.g. Shortening or angulation
B2 Burn contracture Burn scar of skin or soft tissue causing deformity
B3 Spine injury Spinal injury resulting in deformity and/or neurological deficit
B4 Head injury Head injury resulting in neurological
B5 Joint chronic dislocation Joint dislocation that remains unreduced or regularly re-dislocates
B6 Other chronic joint injury Pain or stiffness or swelling or other joint symptom following trauma, but not including dislocation
B7 Tendon/muscle/nerve injury Tendon or muscle or soft tissue or nerve injury or pain following trauma
B8 Amputation Loss of all or part of a limb due to accident or surgery
B9 Other – specify Any other traumatic injury not previously described
CI n f e c t i v e
C1 Joint infection Loss of function of joint associated with history of swelling and fever or discharge
C2 Bone infection limb Pain and or deformity in limb associated with fever, or abscess or discharge of pus
C3 Bone infection spine Pain and or deformity in spine associated with fever, or abscess or discharge of pus
C4 Skin/soft tissue infection/wound Infection of skin or soft tissue including wound infection and ulcers
C5 Other – specify Any other infection affecting the musculoskeletal system not described above
D Neurological
D1 Epilepsy/seizures 2 or more seizures/convulsions not associated with fever
D2 Leprosy Known diagnosis of leprosy
D3 Polio Known polio infection
D4 Para/quadri/tetraplegia Marked weakness or paralysis in arms or legs or both, may be due to injury or other causes
D5 Cp/developmental delay Delay in attaining normal childhood milestones with not obvious physical disorder
D6 Cerebral palsy Nonprogressive motor deficit which started before age 10
D7 Peripheral nerve palsy Weakness due to single nerve lesion e.g. Unilateral foot drop or wrist drop
D8 Other – specify Sensory or motor deficit or neurological disorder not already described
E Other acquired
E1 Joint problem Joint pain or swelling or deformity with no recent preceding trauma
E2 Angular limb deformity Abnormal angulation of limb at or near joint. Kncluded knock knees and bow legs
E3 Bone tumour/swelling Firm swelling of bone – benign or malignant
E4 Skin/soft tissue tumour/swelling Swelling of soft tissue – benign or malignant
E5 Spine deformity Acquired deformity of spine
E6 Spine pain Spinal pain limiting function but not associated with significant deformity
E7 Limb pain Limb pain limiting function, but no structural change
E8 Limb swelling Abnormal swelling of limb (includes lymphoedema)
E9 Other – specify Aquired musculosekeletal impairment not due to infection or trauma, not neurological and not described aboveBMC Musculoskeletal Disorders 2007, 8:30 http://www.biomedcentral.com/1471-2474/8/30
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Training of personnel
Two orthopaedic surgeons, two epidemiologists and a
physiotherapist were responsible for training the survey
team members concerning the screening, the enumera-
tion methodology and the diagnostic process. Three phys-
iotherapists, three nurses and three drivers made three
teams. Other staff included two enumerators, four data
processors, one epidemiological supervisor, one medical
supervisor, one data processing supervisor and a field
study leader. All supervisors accompanied the teams and
worked as field supervisors on differing days
All participants of the survey team underwent training
over a period of three weeks. The physiotherapists and
nurses were trained on the screening tool and diagnosis.
The enumerators were trained in the mapping and seg-
menting process. Inter observer validation was carried out
by repeat examination by the physiotherapists of 59 indi-
viduals who were a mixture of cases and non-cases. Inter
observer agreement was estimated between the physio-
therapists with respect to correctly identifying a case and a
non case, diagnosis, treatment needs and severity A
detailed tool protocol manual was given which included
information outlining responsibilities of team members,
how to complete the tool and the enumeration processes.
Ethics
Ethical approval was obtained from the London School of
Hygiene & Tropical Medicine, and the independent ethics
committee in Rwanda. Permission to proceed was granted
by the government and then consent had to be granted for
each cluster. This involved getting the community leaders'
stamped approval at province, district, sector and cell level
for every cluster that we attended. Each participant gave
verbal approval for examination, and written approval
was taken for any photographs that were taken. All identi-
fied cases were referred to a central community rehabilita-
tion centre where, medical members of the study team
reviewed and referred them on for further treatment.
Results
Screening tool sensitivity and specificity
Of the 93 individuals identified as gold standard cases the
7 screening questions identified 92 of them as cases. Of
the 86 individuals that were identified as gold standard
non-cases the 6 screening questions identified all of them
as non-cases. This gave the screening tool a sensitivity of
97.8% and sensitivity of 98.8% and a positive predictive
value 99%.
Interobserver agreement
Kappa agreement coefficients were calculated for the three
physiotherapists. For agreement on whether an individual
was a case or not the kappa coefficient was 0.92, for the
diagnostic group 0.90, for the precise diagnosis 0.72, for
severity of the case 0.59 and for treatment needed 0.49.
Pilot study
680 eligible individuals were enumerated and 480 were
screened, giving a response rate of 69%. Almost all the
non-responders were unavailable (96%), and few refused
to be examined (4%). The response rate was higher in
rural areas (72%) then in urban areas (62%). The
response rate varied by age group, as there was a lower
response rate (62%) amongst the working age group of
15–50 years and higher in the 0 to 5 year age group
(83%). The response rate was higher in females (75%)
than in males (62%).
38 cases were identified by the screening tool, and only
one individual was identified as a case by the screen that
was subsequently not a case. The sample prevalence of
MSI was 8.1% (95% CI = 5.6–10.6), and this was highest
in peopled aged over 50s (18%, 95% CI 7.0 – 29.0; see
Table 3)). 20 of the cases were female (52.6%). There were
Data Collection Procedures Figure 1
Data Collection Procedures.BMC Musculoskeletal Disorders 2007, 8:30 http://www.biomedcentral.com/1471-2474/8/30
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45 diagnoses of MSI in 38 individuals with MSI (i.e. 7
people had two diagnoses). The most common sub group
of diagnoses being trauma (39%), with 39% other
acquired, 5% infective, 6% neurological and 1% congeni-
tal. The most common diagnoses were amputation (11%)
and spine pain (11%). Other important diagnosis
included fracture malunion and non-union (8.9%) and
seizures (8.9%). The most common aetiological cause of
MSI was trauma (see Table 4). Mild and moderate cases
were each responsible for 42% of cases, and the remaining
16% of cases were severe.
11 of the MSI cases (29%) had not received any treatment
and 89% needed at least one further modality of treat-
ment (see Table 5). 15 cases (41%) needed surgery, while
75% needed physiotherapy. Of those that needed more
treatment 24 (73%) said the reason they had not sought
further treatment was because they could not afford it,
while only 3 (9%) said it was because they did not feel the
need for treatment.
For the responders health today the mean EQ-5D value
for those who were examined without MSI was 66% (S.D.
23%) while for those with MSI it was 45% (S.D. 24%),
giving a mean difference of 20% (95% CI 10–31).
Discussion and conclusion
MSI is an important cause of morbidity and mortality
worldwide [1]. It is likely that the burden of MSI is dispro-
portionately larger in the developing world [4] but this is
an area that has not been researched sufficiently. Esti-
mates of the prevalence and causes of MSI are needed to
plan services, make international comparisons and to
monitor programs. For this to happen tools and method-
ology need to be developed that can measure the preva-
lence and causes of MSI that can be readily used in the
resource-poor developing world.
The 7 question screening tool showed high sensitivity and
specificity for identifying MSI, and a high positive predic-
tive value. The high sensitivity and specificity continued
into the pilot. High inter-observer agreement was
obtained between the examiners in Rwanda, except for
assigning treatment needed (kappa = 0.49). Because of
this low kappa additional training was provided on treat-
ment needs and options for MSIs.
Probability proportionate to size sampling worked well in
the pilot study and an up-to-date sampling frame was
available. For this study to have the security of a probabil-
ity sampling method, we will use the compact segment
sampling method for selecting secondary sampling units
[18]. While this method requires increased skills in map-
ping, and is more complicated in its execution, it reduces
the likelihood of selection bias that could arise if physio-
therapists were allowed to select the households that they
are to attend through the random walk method[18].
Compact segment sampling also facilitates call back at
households where people were unavailable.
The pilot study demonstrated that the new screening and
examination tool that was developed and the sampling
Table 3: Number of cases and MSI prevalence by age group
Age Number of cases (%) Number of people screened (%) Prevalence(%) of MSI by age group (95% CI)
0 to 5 6 (15.8) 94 (20.1) 6.4 (1.3 – 11.4)
6 to 14 4 (10.5) 99 (21.2) 4.0 (0.1 – 8.0)
15 to 50 19 50.0) 225 (48.0) 8.5 (4.8–12.2)
Over 50 9 (23.7) 50 (10.7) 18.0 (7.0 – 290)
Total 38 (100.00) 468 (100.0) 8.1 (5.6 – 10.6)
Table 4: Causes of MSI by aetiology
Number Prevalence % of cases (n = 45) Confidence limits
Family history 3 0.6 6.7 0.1–1.9
Congenital, no family 
history
2 0.4 4.4 0.1–1.5
Perinatal hypoxia 1 0.2 2.2 0.03–0.8
Trauma 16 3.4 35.6 2.0–5.5
Infection 4 0.9 8.9 0.2–2.2
Neoplasm 1 0.2 2.2 0.03–0.8
Unknown 17 3.6 37.8 2.1–5.8
Other 1 0.2 2.2 0.03–0.8
Total (no of diagnoses) 45 100.0BMC Musculoskeletal Disorders 2007, 8:30 http://www.biomedcentral.com/1471-2474/8/30
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methodology proposed for this study are appropriate and
feasible for the purposes of this survey. The pilot study
demonstrated that 80 people was the logistical limit for
any team on one day, especially once travel times had
been considered. The most important issue highlighted by
the pilot for the main study was the response rate which
was lower amongst the males in the study. The need for
good participation of the community leaders was noted
by the teams. In clusters where they were fully involved in
both segmenting and on survey day there was a better
response. Additionally the lower response rate in urban
areas was often because people were at work and so dur-
ing the main study the plan will be to carry out urban clus-
ters later in the day and on weekends.
Overall this approach is appropriate for measuring the
prevalence of MSI in Rwanda. Studies investigating the
prevalence of conditions causing MSI are important steps
to building sound epidemiological understanding of the
nature of these disorders to enable appropriate public
health planning.
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